GlassScriptPhysician profile
Shyam Patel
NPI 1326428533
$7,638.37
in general payments reported to CMS, 2019-2025
23 companies · $4,207 in 2025
The $4,207 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $901 · 2020: $58.35 · 2021: $249 · 2022: $395 · 2023: $674 · 2024: $1,153 · 2025: $4,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,336 · Travel and Lodging: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,336.05 |
| Travel and Lodging | $698.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $2,288.81 | 2020-2025 | |
| Globus Medical, INC. | $1,770.51 | 2023-2025 | Sable, Excelsius Gps, Modulus |
| Mallinckrodt Hospital Products INC. | $485.00 | 2022-2025 | Acthar |
| Alcon Vision LLC | $455.22 | 2019-2025 | Clareon, Simbrinza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $344.67 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $292.48 | 2019-2025 | Cequa |
| Abbvie INC. | $277.01 | 2022-2025 | |
| Dompe US, INC. | $266.78 | 2021-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $246.24 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $216.84 | 2019-2025 | Tecnis Simplicity |
| Oyster Point Pharma, INC. | $156.42 | 2022-2024 | Tyrvaya |
| Bausch & Lomb Americas INC. | $155.30 | 2022-2023 | Miebo |
| Tarsus Pharmaceuticals, INC. | $113.08 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $69.99 | 2023-2024 | Dextenza |
| Eyevance Pharmaceuticals LLC | $61.67 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $54.49 | 2023 | Tepezza |
| Ani Pharmaceuticals, INC. | $50.24 | 2022 | |
| Thea Pharma INC. | $44.27 | 2024 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $40.56 | 2021 | |
| Amgen INC. | $28.92 | 2024 | Tepezza |
| Rxsight INC | $20.45 | 2024 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Harrow Eye, LLC | $20.00 | 2024 | Vevye |
| Mallinckrodt Enterprises LLC | $18.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shyam Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.